Ask AI
ProCE Banner Activity

DESTINY-Breast09: Phase III Trial of Trastuzumab Deruxtecan ± Pertuzumab vs THP as 1L Treatment of HER2+ Advanced/Metastatic Breast Cancer

Conference Coverage
Slideset

In this interim analysis of the randomized phase III DESTINY-Breast09 trial, T-DXd + pertuzumab demonstrated a statistically significant and clinically meaningful improvement in PFS vs standard first-line treatment with THP for patients with advanced or metastatic breast cancer. 

Released: June 04, 2025

Expiration: December 03, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.